DOI: http://dx.doi.org/10.18203/2349-2902.isj20210366

Role of intralesional bleomycin in recurrent or residual keloids and hypertrophic scars

Bharat Mishra, Chetna Arora

Abstract


Background: Keloids and hypertrophic scars are difficult to treat. There are many modalities available with variable success rate. Triamcinolone is still the most commonly used drug but recurrence and partial response to this conventional treatment is still a major concern. Many studies have proved the role and efficacy of intralesional bleomycin and this study was done to assess the role of intralesional bleomycin in recurrent and residual lesions.

Methods: The patients with recurrent lesion or residual lesions after the injection of triamcinolone were enrolled in the study. Patients received local infiltration of bleomycin. The injections were scheduled at monthly intervals for three consecutive months. They were followed at 1st, 2nd, 3rd, and 12th months. Scar assessment was done by calculating its volume, Vancouver scar scale (VSS) and visual analogue score (pain and pruritis). Side effects were also recorded. Final assessment was done at 1year for any recurrence.

Results: Twenty-five patients completed the study. The most common location of scars was presternal (52%) and trauma was the most common cause in scars (20%). We observed the decrease of volume of 75.85% which was highly significant on statistical analysis (p=0.001). Similarly, statistically significant difference was noticed in VSS, VAS for pain and pruritis. No systemic side effects were noticed. No recurrence was noted at the end of 12 months.

Conclusion: Intralesional bleomycin is found to be useful in management of recurrent or residual lesions. It can be a potential option in the management of recurrent and residual hypertrophic scars and keloids.


Keywords


Recurrent keloids, Residual keloids, Recurrent hypertrophic scars, Intralesional bleomycin

Full Text:

PDF

References


Niessen F, Spauwen P, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999;104(5):1435-58.

Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg. 2001;27:23-7.

Saray Y, Güleç AT. Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: A preliminary study. Int J Dermatol. 2005;44:777-84

Naeini FF, Najafian J, Ahmadpour K. Bleomycin tattooing as a promising therapeutic modality in large keloids and hypertrophic scars. Dermatol Surg. 2006;32:1023-9;

Aggarwal H, Saxena A, Lubana PS, Mathur RK, Jain DK. Treatment of keloids and hypertrophic scars using bleom. J Cosmet Dermatol. 2008;7(1):43-9.

Manca G, Pandolfi P, Gregorelli C, Cadossi M, De Terlizzi F. Treatment of keloids and hypertrophic scars with bleomycin and electroporation. Plast Reconstr Surg. 2013;132(4):621e-30.

Nedelec B, Shankowsky A, Tredgett EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil. 2000;21:205-12.

Sullivan T, Smith J, Kermode J, McIver E, Courtemanche DJ. Rating the burn scar. J Burn Care Rehabil. 1990;11:256-60.

Draaijers LJ, Tempelman FR, Botman YA, Tuinebreijer WE, Middelkoop E, Kreis RE. The Patient and Observer Scar Assessment Scale: a reliable and feasible tool for scar evaluation. Plast Reconstr Surg. 2004;113:1960-65.

Larrabe WF, East CA, Jaffe HS, Stepheson C, Peterson KE. Intralesional interferon gamma treatment for keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg. 1990;116:1159-62.

Jackson IT, Bhageshpur R, DiNick V, Khan A, Bhaloo S. Investigation of recurrence rates among earlobe keloids utilizing various postoperative therapeutic modalities. Eur J Plast Surg. 2001;24(2):88-95.

Hendricks T, Martens MF, Huyben CM, Wobbes T. Inhibition of basal and TGF betainduced fibroblast collagen synthesis by antineoplastic agents. Implications for wound healing. Br J Cancer. 1993;67:545-50.